The Chicago Entrepreneur

Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.

Previous post Nelson Peltz steps down as chair of Wendy’s board, starting a new era for burger chain
Next post Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial